|Bid||5.54 x 800|
|Ask||5.99 x 1400|
|Day's Range||5.43 - 5.90|
|52 Week Range||3.18 - 13.84|
|Beta (5Y Monthly)||2.49|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.83|
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) shareholders will doubtless be very grateful to see the share price up 33...
Lewis "Rusty" Williams founded Five Prime Therapeutics nearly 20 years ago. Now he, the co-inventor of the cancer drug Opdivo and two other Five Prime executives are deep into a new startup.
Five Prime Therapeutics Announces Resignation of Dr. Lewis T. "Rusty" Williams from Board of Directors
New York-born, Bay Area-raised Brian Wong is doing the hard work of broadening a drug pipeline with what he describes as a “Brooklyn toughness."
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today presented initial safety data from the Phase 1 clinical trial of FPT155 in patients with advanced solid tumors in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, Maryland. “FPT155 is a first-in-class CD80 fusion protein with potential dual mechanisms to activate T cells,” said Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therapeutics.
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -8.42% and -31.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced its results for the third quarter and provided an update on the company’s recent activities.
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2019 financial results on Wednesday, November 6, 2019 after the U.S.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...
This cancer-fighting biotech was one of the early companies to commit to The Cove at Oyster Point; now it may sublease some or all of its space.
Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, announced today a corporate restructuring to extend the company’s cash runway without impacting or delaying the data timelines of its clinical programs. The company will retain a small research group focused on advancing three wholly-owned, late-stage research assets and will increasingly rely on outsourcing and contracted capabilities. “My immediate focus as CEO has been to conduct a review of Five Prime’s operations with the goal of ensuring long-term sustainability and value creation,” said William Ringo, Chairman and Interim Chief Executive Officer of Five Prime Therapeutics.
- Results Provide First Clinical Demonstration of B7-H4 as a Potential Therapeutic Target and Continue to Support FPA150’s Greatest Potential in Combination Therapy -
If you want to know who really controls Five Prime Therapeutics, Inc. (NASDAQ:FPRX), then you'll have to look at the...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -15.12% and -39.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?